Personalized Medicine Using Omics Approaches in Acute Respiratory Distress Syndrome to Identify Biological Phenotypes

Overview

Journal Respir Res

Specialty Pulmonary Medicine

Date 2022 Nov 19

PMID 36403043

Authors

Denise Battaglini

Loui Al-Husinat

Ana Gabriela Normando

Adriana Paes Leme

Kleber Franchini

Marcelo Morales

Paolo Pelosi

Patricia Rm Rocco

Affiliations

Soon will be listed here.

Abstract

In the last decade, research on acute respiratory distress syndrome (ARDS) has made considerable progress. However, ARDS remains a leading cause of mortality in the intensive care unit. ARDS presents distinct subphenotypes with different clinical and biological features. The pathophysiologic mechanisms of ARDS may contribute to the biological variability and partially explain why some pharmacologic therapies for ARDS have failed to improve patient outcomes. Therefore, identifying ARDS variability and heterogeneity might be a key strategy for finding effective treatments. Research involving studies on biomarkers and genomic, metabolomic, and proteomic technologies is increasing. These new approaches, which are dedicated to the identification and quantitative analysis of components from biological matrixes, may help differentiate between different types of damage and predict clinical outcome and risk. Omics technologies offer a new opportunity for the development of diagnostic tools and personalized therapy in ARDS. This narrative review assesses recent evidence regarding genomics, proteomics, and metabolomics in ARDS research.

Citing Articles

A narrative review on the future of ARDS: evolving definitions, pathophysiology, and tailored management.

Al-Husinat L, Azzam S, Al Sharie S, Araydah M, Battaglini D, Abushehab S Crit Care. 2025; 29(1):88.

PMID: 39994815 PMC: 11852867. DOI: 10.1186/s13054-025-05291-0.

Increased pro-SFTPB in HDL promotes the pro-inflammatory transition of HDL and represents a sign of poor prognosis in ARDS patients.

Yang L, Xu Z, Wang Z, Ding F, Wu Z, Shi X J Transl Med. 2025; 23(1):75.

PMID: 39819672 PMC: 11740663. DOI: 10.1186/s12967-025-06100-6.

Editorial: Personalized therapy in ARDS, volume II.

Battaglini D, Guerin C, Rocco P Front Med (Lausanne). 2024; 11:1533593.

PMID: 39736977 PMC: 11683102. DOI: 10.3389/fmed.2024.1533593.

Advancing Cardiac Amyloidosis Care Through Insights from Cardiopulmonary Exercise Testing.

Pugliatti P, Trimarchi G, Barocelli F, Pizzino F, Di Spigno F, Tedeschi A J Clin Med. 2024; 13(23).

PMID: 39685743 PMC: 11642058. DOI: 10.3390/jcm13237285.

Glucocorticoid therapy for acute respiratory distress syndrome: Current concepts.

Zhao Y, Yao Z, Xu S, Yao L, Yu Z J Intensive Med. 2024; 4(4):417-432.

PMID: 39310055 PMC: 11411438. DOI: 10.1016/j.jointm.2024.02.002.

References

Bhargava M, Viken K, Wang Q, Jagtap P, Bitterman P, Ingbar D . Bronchoalveolar Lavage Fluid Protein Expression in Acute Respiratory Distress Syndrome Provides Insights into Pathways Activated in Subjects with Different Outcomes. Sci Rep. 2017; 7(1):7464. PMC: 5547130. DOI: 10.1038/s41598-017-07791-8. View

Jiang W, Zhao K, Yuan W, Zhou F, Song H, Liu G . MicroRNA-31-5p Exacerbates Lipopolysaccharide-Induced Acute Lung Injury via Inactivating Cab39/AMPK Pathway. Oxid Med Cell Longev. 2020; 2020:8822361. PMC: 7568166. DOI: 10.1155/2020/8822361. View

Battaglini D, Lopes-Pacheco M, Castro-Faria-Neto H, Pelosi P, Rocco P . Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19. Front Immunol. 2022; 13:857573. PMC: 9091347. DOI: 10.3389/fimmu.2022.857573. View

Ding Y, Feng Q, Chen J, Song J . TLR4/NF-κB signaling pathway gene single nucleotide polymorphisms alter gene expression levels and affect ARDS occurrence and prognosis outcomes. Medicine (Baltimore). 2019; 98(26):e16029. PMC: 6617146. DOI: 10.1097/MD.0000000000016029. View

Wu X, Wu C, Gu W, Ji H, Zhu L . Serum Exosomal MicroRNAs Predict Acute Respiratory Distress Syndrome Events in Patients with Severe Community-Acquired Pneumonia. Biomed Res Int. 2019; 2019:3612020. PMC: 6699276. DOI: 10.1155/2019/3612020. View

Izquierdo-Garcia J, Nin N, Jimenez-Clemente J, Horcajada J, Arenas-Miras M, Gea J . Metabolomic Profile of ARDS by Nuclear Magnetic Resonance Spectroscopy in Patients With H1N1 Influenza Virus Pneumonia. Shock. 2018; 50(5):504-510. DOI: 10.1097/SHK.0000000000001099. View

OMahony D, Glavan B, Holden T, Fong C, Black R, Rona G . Inflammation and immune-related candidate gene associations with acute lung injury susceptibility and severity: a validation study. PLoS One. 2012; 7(12):e51104. PMC: 3522667. DOI: 10.1371/journal.pone.0051104. View

Rautanen A, Mills T, Gordon A, Hutton P, Steffens M, Nuamah R . Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study. Lancet Respir Med. 2014; 3(1):53-60. PMC: 4314768. DOI: 10.1016/S2213-2600(14)70290-5. View

Brown S, Grissom C, Rondina M, Hoidal J, Scholand M, Wolff R . Polymorphisms in key pulmonary inflammatory pathways and the development of acute respiratory distress syndrome. Exp Lung Res. 2014; 41(3):155-62. PMC: 4406221. DOI: 10.3109/01902148.2014.983281. View

10.

Jabaudon M, Berthelin P, Pranal T, Roszyk L, Godet T, Faure J . Receptor for advanced glycation end-products and ARDS prediction: a multicentre observational study. Sci Rep. 2018; 8(1):2603. PMC: 5805783. DOI: 10.1038/s41598-018-20994-x. View

11.

Griffiths M, McAuley D, Perkins G, Barrett N, Blackwood B, Boyle A . Guidelines on the management of acute respiratory distress syndrome. BMJ Open Respir Res. 2019; 6(1):e000420. PMC: 6561387. DOI: 10.1136/bmjresp-2019-000420. View

12.

Liu K, Glidden D, Eisner M, Parsons P, Ware L, Wheeler A . Predictive and pathogenetic value of plasma biomarkers for acute kidney injury in patients with acute lung injury. Crit Care Med. 2007; 35(12):2755-61. PMC: 3293249. View

13.

Jones T, Feng R, Kerchberger V, Reilly J, Anderson B, Shashaty M . Plasma sRAGE Acts as a Genetically Regulated Causal Intermediate in Sepsis-associated Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2019; 201(1):47-56. PMC: 6938154. DOI: 10.1164/rccm.201810-2033OC. View

14.

Huang Y, Huang L, Zhu G, Pei Z, Zhang W . Downregulated microRNA-27b attenuates lipopolysaccharide-induced acute lung injury via activation of NF-E2-related factor 2 and inhibition of nuclear factor κB signaling pathway. J Cell Physiol. 2018; 234(5):6023-6032. DOI: 10.1002/jcp.27187. View

15.

Bime C, Pouladi N, Sammani S, Batai K, Casanova N, Zhou T . Genome-Wide Association Study in African Americans with Acute Respiratory Distress Syndrome Identifies the Selectin P Ligand Gene as a Risk Factor. Am J Respir Crit Care Med. 2018; 197(11):1421-1432. PMC: 6005557. DOI: 10.1164/rccm.201705-0961OC. View

16.

Lee L, Eghbali M, Sapru A . A novel miRNA biomarker panel associated with mortality in pediatric patients with ARDS. Respir Res. 2021; 22(1):169. PMC: 8177032. DOI: 10.1186/s12931-021-01761-5. View

17.

Evans C, Karnovsky A, Kovach M, Standiford T, Burant C, Stringer K . Untargeted LC-MS metabolomics of bronchoalveolar lavage fluid differentiates acute respiratory distress syndrome from health. J Proteome Res. 2013; 13(2):640-9. PMC: 4068805. DOI: 10.1021/pr4007624. View

18.

Gong M . Genetic epidemiology of acute respiratory distress syndrome: implications for future prevention and treatment. Clin Chest Med. 2006; 27(4):705-24. PMC: 2703471. DOI: 10.1016/j.ccm.2006.07.001. View

19.

Glavan B, Holden T, Goss C, Black R, Neff M, Nathens A . Genetic variation in the FAS gene and associations with acute lung injury. Am J Respir Crit Care Med. 2010; 183(3):356-63. PMC: 3056231. DOI: 10.1164/rccm.201003-0351OC. View

20.

Marshall R, Webb S, Hill M, Humphries S, Laurent G . Genetic polymorphisms associated with susceptibility and outcome in ARDS. Chest. 2002; 121(3 Suppl):68S-69S. DOI: 10.1378/chest.121.3_suppl.68s. View